For the quarter ending 2026-03-31, PCSA has $4,520,974 in assets. $1,980,093 in debts. $1,691,043 in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Other | - | - | - | 5,535 |
| Right-of-use assets, net | - | - | - | 24,318 |
| Total other assets | - | - | - | 29,853 |
| Cash and cash equivalents | 1,691,043 | 5,536,955 | 6,308,420 | 6,936,620 |
| Prepaid expenses and other | 247,363 | 133,919 | 278,342 | 217,201 |
| Total current assets | 1,938,406 | 5,670,874 | 6,586,762 | 7,153,821 |
| Digital assets at fair value | 1,585,356 | 1,145,180 | - | - |
| Prepaid expenses | 993,701 | 993,701 | 993,701 | 993,701 |
| Total non-current assets | - | - | - | 993,701 |
| Property and equipment, net | - | - | - | 4,414 |
| Equipment, net | 3,511 | 3,812 | 4,113 | - |
| Total assets | 4,520,974 | 7,813,567 | 7,584,576 | 8,181,789 |
| Accounts payable | 840,370 | 1,056,796 | 727,172 | 785,754 |
| Current maturities of lease liability | - | - | - | 25,584 |
| Accrued expenses | 1,139,723 | 1,179,457 | 1,023,806 | 1,263,243 |
| Total current liabilities | 1,980,093 | 2,236,253 | 1,750,978 | 2,074,581 |
| Non-current lease liability | - | - | - | 0 |
| Total liabilities | 1,980,093 | 2,236,253 | 1,750,978 | 2,074,581 |
| Common stock, par value 0.0001, 1,000,000,000 shares authorized 2,677,835 issued and outstanding at march 31, 2026 2,572,114 issued and 2,571,914 outstanding at december 31, 2025 | 269 | 257 | 5,287 | 4,029 |
| Additional paid-in capital | 106,700,824 | 106,660,090 | 103,552,406 | 100,390,701 |
| Treasury stock, 200 shares at cost | - | 300,000 | 300,000 | 300,000 |
| Accumulated deficit | -104,160,212 | -100,783,033 | -97,424,095 | -93,987,522 |
| Total stockholders equity | 2,540,881 | 5,577,314 | 5,833,598 | 6,107,208 |
| Total liabilities and stockholders equity | 4,520,974 | 7,813,567 | 7,584,576 | 8,181,789 |
Processa Pharmaceuticals, Inc. (PCSA)
Processa Pharmaceuticals, Inc. (PCSA)